Vistin Pharma

AGM Information • May 22, 2025

PROTOKOLL FRA	MINUTES FROM
ORDINÆR GENERALFORSAMLING I	ANNUAL GENERAL MEETING IN
VISTIN PHARMA ASA	VISTIN PHARMA ASA*
Ordinær generalforsamling i Vistin Pharma ASA ("Vistin Pharma" eller "Selskapet") ble avholdt mandag 22. mai 2025 kl. 13:00 i Østensjøveien 27, Oslo.	The annual general meeting in Vistin Pharma ASA ("Vistin Pharma" or "the Company") was held May 22, 2025 at 1300 hrs (CET) at Østensjøveien 27, Oslo.
1. Åpning av møtet og registrering av deltakende aksjonærer	1. Opening of the meeting and registration of participating shareholders
Styreleder Øyvin A. Brøymer åpnet møtet.	The Chairman, Øyvin A. Brøymer, opened the meeting.
Tilstede var totalt 24 446 025 aksjer, herav 8 147 785 aksjer representert ved fullmakt. Således var 55,13% av Selskapets samlede aksjekapital representert på generalforsamlingen.	Present were in total 24 446 025 shares, including 8 147 785 shares represented by proxy. Thus, approximately 55.13% of the Company's total share capital was represented at the general meeting.
2. Valg av møteleder og person til å signere protokollen sammen med møteleder	2. Election of meeting Chairman and a person to co-sign the minutes
Følgende beslutning ble fattet:	The following resolution was passed:
"Øyvin A. Brøymer velges til møteleder. Magnus W. Tolleshaug velges til å medundertegne protokollen."	"Øyvin A. Brøymer is elected to chair the meeting. Magnus W. Tolleshaug is elected to co-sign the minutes."
3. Godkjennelse av innkalling og saker til behandling	3. Approval of the notice of the meeting and the agenda
Det fremkom ingen innsigelser mot innkallingen og dagsordenen, og følgende beslutning ble fattet:	There were no objections to the notice and the agenda, and the following resolution was passed:
"Innkalling og dagsorden godkjennes".	"The notice of and agenda for the meeting are approved."
4. Godkjennelse av årsregnskap og årsberetning for 2024	4. Approval of annual financial statement and the Directors' report for 2024
Følgende vedtak ble fattet:	The following resolution was passed:
"Generalforsamlingen godkjenner års-regnskapet samt styrets beretning for 2024. Generalforsamlingen godkjenner å utbetale et ordinært utbytte til aksjonærene på totalt NOK 1,25 per aksje, med utbetaling i juni. Utbytte utdeles som en tilbakebetaling av innbetalt kapital (overkurs).''	"The General Meeting approves the Annual Financial Statements and the Directors' Report for 2024. The General Meeting approves to pay out an ordinary dividend to shareholders of NOK 1,25 per share. Dividend will be distributed as a repayment of paid-in capital (share premium).''
5. Honorar til styrets og valgkomitéens medlemmer	5. Remuneration for the board of directors and the election committee
Følgende beslutning ble fattet:	The following resolution was passed:
"Innstillingen fra valgkomiteen godkjennes. Det årlige honoraret til styremedlemmene for perioden mellom ordinær generalforsamling i mai 2025 og til ordinær generalforsamling i 2026 skal være: Styrets leder NOK 490 000	"The recommendation from the Election Committee is approved. The annual remuneration to the board members for the period from the ordinary general meeting in May 2025 and to the annual general meeting in 2026 for the Chairman of the Board and Board members:
Andre styremedlemmer NOK 264 000	Chairman of the Board NOK 490,000 Other Board members NOK 264,000

Honoraret til valgkomiteen og kompensasjonskomiteen for perioden fra den ordinære generalforsamlingen i 2025 til den ordinære generalforsamlingen i 2026 fastsettes til:	The remuneration to the Election Committee and the Remuneration Committee for the period from the ordinary general meeting in 2025 and to the annual general meeting in 2026 shall be:
Leder i valgkomiteen NOK 30 000 Medlem i valgkomiteen NOK 25 000 Kompensasjonskomiteen NOK 25 000"	Chairman of the Committee NOK 30,000 Members of the Committee NOK 25,000
	Remuneration Committee NOK 25,000"
6. Honorar til revisor	6. Auditor's remuneration
Følgende vedtak ble fattet:	The following resolution was passed:
"Generalforsamlingen godkjenner revisors honorar for revisjonen av årsregnskapet til Vistin Pharma ASA for 2024 etter regning."	"The general meeting approves the auditor's remuneration for audit of the Annual Financial Statements of Vistin Pharma ASA for the financial year of 2024 in accordance with invoice."
7. Styrets erklæring om fastsettelse av lønn og annen godtgjørelse til ledende ansatte	7. The Board's statement regarding determination of salary and other compensation to leading employees
Styrets erklæring om lederlønnsfastsettelse i henhold til allmennaksjeloven § 6-16a & b og tilhørende forskrift; en rapport om lønn og annen godtgjørelse til ledende personer, ble gjennomgått.	The Board's statement on compensation to leading employees in accordance with the Norwegian Public Limited Companies Act ("the Act") section 6-16a & b and associated regulations; a report on remuneration to leading employees was discussed.
Følgende vedtak ble fattet:	The following resolution was passed:
Del 1:	Part 1:
"Generalforsamlingen gir sin tilslutning til styrets erklæring om lønn og annen godtgjørelse til ledende ansatte."	"The General Meeting supports the statement of the Board regarding compensation to leading employees."
Del 2:	Part 2:
"Generalforsamlingen godkjenner styrets erklæring om langsiktige insentiv ordninger."	"The General Meeting adopts the statement of the Board regarding long term incentive plans."
8. Godkjennelse av finansieringsbistand til ledende ansatte ifm. kjøp av aksjer i selskapet under langsiktig insentivavtale.	8. Approval of financial assistance to purchase shares in relation to the company's long-term incentive plan.
Styrets erklæring og redegjørelse, som var vedlagt innkallingen, i forbindelse med finansieringsbistand for kjøp av aksjer i selskapet til ledende ansatte ble gjennomgått.	The statement and declaration prepared by the Board, which was attached to the notice, in relation to financial assistance to purchase shares in the company was discussed.
Følgende vedtak ble fattet:	The following resolution was passed:
"Generalforsamlingen godkjenner at selskapet stiller en låneramme på NOK 5 000 000 tilgjengelig for selskapets ledende ansatte. Lånerammen har en varighet på tre år, og kan kun benyttes til finansiering av aksjekjøp i selskapet."	"The General meeting approved a loan facility of NOK 5 000 000 to the executive management. The loan facility has a duration of three years and can only be used as financing for purchasing of shares in the company."
9. Valg av medlemmer til styret	9. Election of members to the board of directors
Valgkomiteen har mottatt en forespørsel fra Øystein Stray Spetalen om at han ikke ønsker gjenvalg som styremedlem i Vistin Pharma ASA. Valgkomiteens konklusjon er at Øystein Spetalen ikke foreslås erstattet med et nytt styremedlem og at styret dermed reduseres med ett styremedlem.	The Election Committee has received a request from Øystein Stray Spetalen that he does not want to be re elected as a board member of Vistin Pharma ASA. The Election Committee's conclusion is that Øystein Spetalen is not proposed to be replaced with a new board member and that the board is thereby reduced by one board member.

Følgende vedtak ble fattet:	The following resolution was passed:
''Innstillingen fra valgkomiteen om å gjenvelge Øystein Stray Spetalen som styremedlem ble derfor trukket.''	''The recommendation from the Election committee to re-elect Øystein Stray Spetalen as a Board member was therefore withdrawn.''
Styret består da av følgende aksjonærvalgte og ansatte valgte medlemmer:	The Board consists of the following shareholder and employee elected members:
• Øyvin A. Brøymer (Styreleder) • Bettina Banoun • Kari Krogstad • Espen Marcussen • Espen Lia Gregoriussen (ansatte representant) • Stine Wang Rønningen (ansatte representant) • Kjell-Erik Nordby (observatør)"	• Øyvin A. Brøymer (Chairman) • Bettina Banoun • Kari Krogstad • Espen Marcussen • Espen Lia Gregoriussen (employee representative) Stine Wang Rønningen (employee representative) • • Kjell-Erik Nordby (observer)"
10. Valg av medlemmer til valgkomiteen	10. Election of members to the nomination committee
Følgende vedtak ble fattet:	The following resolution was passed:
"Følgende velges som medlemmer av valgkomiteen for en periode på 2 (to) år, frem til den ordinære generalforsamling 2027:	"The Election Committee proposes that the following are elected as members of the board of directors for a period of 2 (two) years, until the annual general meeting 2027:
Eivind Devold (leder) • • Nils Erling Ødegaard	• Eivind Devold (Chairman) • Nils Erling Ødegaard
11. Valg av revisor	11. Election of Auditor
Følgende vedtak ble truffet:	The following resolution was passed:
"Generalforsamlingen godkjenner at EY fortsetter som revisor for Vistin Pharma ASA"	"The General Meeting approves that EY will continue as auditor for Vistin Pharma ASA''
12. Fullmakt til å utstede aksjer	12. Authorization to issue shares
Følgende vedtak ble truffet:	The following resolution was passed:
"Styret gis fullmakt til å øke aksjekapitalen med inntil NOK 8 868 918 gjennom én eller flere aksjekapitalutvidelser.	"The Board is granted authorization to increase the share capital with up to NOK 8 868 918, through one or several share capital increases.
Fullmakten skal kunne anvendes for følgende formål:	The authorization may be used for one or more of the following purposes:
(i) for å gi Selskapet finansiell fleksibilitet, herunder ved investeringer, oppkjøp og fusjoner.	(i) to provide the Company with financial flexibility, including in connection with investments, mergers and acquisitions.
Pris og tegningsvilkår fastsettes av styret ved hver utstedelse under hensyn til Selskapets behov og aksjenes markedsverdi på det aktuelle tidspunkt. Aksjer vil kunne utstedes mot kontantvederlag eller vederlag i form av andre aktiva (tingsinnskudd).	Price and conditions for subscription will be determined by the Board on issuance, according to the Company's needs and the shares' market value at the time. Shares may be issued in exchange for cash settlement or contribution in kind.
Eksisterende aksjonærers fortrinnsrett til å tegne aksjer vil kunne bli fraveket av styret i forbindelse med utøvelse av fullmakten.	The existing shareholders pre-emptive rights to subscribe shares can be deviated from in connection with the effectuation of this authorization.
Denne fullmakt utløper på datoen for den ordinære generalforsamlingen i 2026, men skal i alle tilfelle utløpe senest 15 måneder fra datoen for denne generalforsamlingen.	The Board's authorization is valid until the Annual General Meeting in 2026, but shall in any event expire at the latest 15 months from the date of this annual general meeting.
Styret gis samtidig fullmakt til å foreta nødvendige vedtektsendringer ved utøvelse av fullmakten."	The Board is at the same time given authorization to make the necessary amendments to the articles of association on execution of the authorization."

13. Fullmakt til å erverve egne aksjer	13. Authorization to acquire treasury shares
Følgende vedtak ble fattet:	The following resolution was passed:
"Styret gis fullmakt til på Selskapets vegne å erverve aksjer i Vistin Pharma ASA til ett eller flere av følgende formål:	"The Board is granted authorization to acquire shares in Vistin Pharma ASA on behalf of the Company for one or more of the following purposes:
(i) for å øke aksjonærenes avkastning.	(i) to increase return on investment for the Company's shareholders.
Fullmakten gjelder for kjøp av inntil 10 % av pålydende av Selskapets aksjekapital, jf. allmennaksjeloven §§ 9-2 og 9- 3. Aksjer kan erverves til minst NOK 1 per aksje og maksimalt NOK 100 per aksje. Disse begrensninger skal justeres tilsvarende i tilfelle av aksjespleis, aksjesplitt og lignende transaksjoner. Aksjene skal erverves ved ordinær omsetning over børs. Styrets fullmakt gjelder frem til den ordinære generalforsamlingen i 2026, men skal i alle tilfelle utløpe senest 15 måneder fra datoen for denne generalforsamlingen. Beslutningen skal meldes til og registreres av Foretaksregisteret innen aksjer erverves i henhold til fullmakten."	The authorization covers purchase(s) of up to 10% of the face value of the share capital of the Company, cf. the public limited liability companies act §§ 9-2 and 9-3. Shares may be acquired at minimum NOK 1 per share and maximum NOK 100 per share. These limitations shall be adjusted in the event of share consolidation, share splits, and similar transactions. The shares shall be acquired through ordinary purchase on the stock exchange. The Board's authorization is valid until the annual general meeting in 2026, but shall in any event expire at the latest 15 months from the date of this General Meeting. The decision shall be notified to and registered by the Norwegian Register of Business Enterprises prior to acquiring any shares pursuant to this authorization."
Da det ikke forelå flere saker til behandling, takket møteleder for oppmøtet, og møtet ble hevet.	As there were no further matters on the agenda, the Chairman thanked the present shareholders for their participation, and the meeting was adjourned.
Vedlagt følger en detaljert oversikt over utfallet av avstemningene, herunder blant annet antall stemmer for og mot de respektive beslutningene, jf allmennaksjeloven § 5-16.	Attached is a detailed overview of the results and voting, including the number of votes for and against the respective resolutions, cf the Norwegian public limited companies act section 5-16.
*	*
Signatur følger på neste side.	The signature follows on the next page.

* These minutes are prepared in Norwegian, with an English office translation. In case of discrepancies between the two versions, the Norwegian version shall prevail.

Signature page for Vistin Pharma ASA Annual General Meeting 2025

Oslo, 22. Mai, 2025/ Oslo, May 22nd, 2025

___________________________ Øyvin A. Brøymer

___________________________ Magnus W. Tolleshaug

Sign.

Sign.

Total Represented

ISIN:	NO0010734122 VISTIN PHARMA ASA
General meeting date: 22/05/2025 13.00
Today:	22.05.2025

Number of persons with voting rights represented/attended : 2

	Number of shares % sc
Total shares	44,344,592
- own shares of the company	0
Total shares with voting rights	44,344,592
Represented by own shares	14,509,280	32.72 %
Represented by advance vote	1,788,960	4.03 %
Sum own shares	16,298,240 36.75 %
Represented by proxy	5,156,012	11.63 %
Represented by voting instruction	2,991,773	6.75 %
Sum proxy shares	8,147,785	18.37 %
Total represented with voting rights	24,446,025	55.13 %
Total represented by share capital	24,446,025	55.13 %

Registrar for the company:

Signature company:

NORDEA BANK ABP, FILIAL NORGE

VISTIN PHARMA ASA

Protocol for general meeting VISTIN PHARMA ASA

ISIN: NO0010734122 VISTIN PHARMA ASA

General meeting date: 22/05/2025 13.00 Today: 22.05.2025

Shares class	For	Against Poll in				Abstain Poll not registered Represented shares with voting rights
Agenda item 2 Election of the chairman of the meeting and a person to co-signthe minutes
Ordinær	24,446,025	0	24,446,025	0	0	24,446,025
votes cast in %	100.00 %	0.00 %		0.00 %
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %
total sc in %	55.13 %	0.00 %	55.13 %	0.00 %	0.00 %
Total	24,446,025	0	24,446,025	0	0	24,446,025
Agenda item 3 Approval of the notice of the meeting and the agenda
Ordinær	24,446,025	0	24,446,025	0	0	24,446,025
votes cast in %	100.00 %	0.00 %		0.00 %
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %
total sc in %	55.13 %	0.00 %	55.13 %	0.00 %	0.00 %
Total	24,446,025	0	24,446,025	0	0	24,446,025
Agenda item 4 Approval of the annual financial statements and the Directors report for 2024
Ordinær	24,446,025	0	24,446,025	0	0	24,446,025
votes cast in %	100.00 %	0.00 %		0.00 %
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %
total sc in %	55.13 %	0.00 %	55.13 %	0.00 %	0.00 %
Total	24,446,025		0 24,446,025	0	0	24,446,025
Agenda item 5 Approval of remuneration for the Board of Directors, theElection Committee and the
Remuneration Committee
Ordinær	24,446,025	0	24,446,025	0	0	24,446,025
votes cast in %	100.00 %	0.00 %		0.00 %
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %
total sc in %	55.13 %	0.00 %	55.13 %	0.00 %	0.00 %
Total	24,446,025	0	24,446,025	O	0	24,446,025
Agenda item 6 Approval of auditors remuneration
Ordinær	24,446,025	0	24,446,025	0	0	24,446,025
votes cast in %	100.00 %	0.00 %		0.00 %
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %
total sc in %	55.13 %	0.00 %	55.13 %	0.00 %	0.00 %
Total	24,446,025	0	24,446,025	0	0	24,446,025
Agenda item 7.1 The General Meeting supports the statement of the Board regarding compensation to leading employees
Ordinær	24,446,025	0	24,446,025	0	0	24,446,025
votes cast in %	100.00 %	0.00 %		0.00 %
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %
total sc in %	55.13 %	0.00 %	55.13 %	0.00 %	0.00 %
Total	24,446,025		0 24,446,025	0	0	24,446,025
Agenda item 7.2 The General Meeting adopts the statement of the Board regarding long term incentive
plans and measures for keeping key personnel Ordinær	24,446,025			0	0
votes cast in %	100.00 %	0 0.00 %	24,446,025	0.00 %		24,446,025
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %
total sc in %	55.13 %	0.00 %	55.13 %	0.00 %	0.00 %
Total	24,446,025		0 24,446,025	0	0	24,446,025
Agenda item 8 Approval of financial assistance to purchase shares in relation tothe companys long-term
incentive plan.
Ordinær	24,446,025	0	24,446,025	0	0	24,446,025
votes cast in %	100.00 %	0.00 %		0.00 %
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %
total sc in %	55.13 %	0.00 %	55.13 %	0.00 %	0.00 %
Total	24,446,025	0	24,446,025	0	0	24,446,025
Agenda item 9 Election of members to the Board of Directors
Ordinær	24,376,919	69,106	24,446,025	0	0	24,446,025
votes cast in %	99.72 %	0.28 %		0.00 %
representation of sc in %	99.72 %	0.28 %	100.00 %	0.00 %	0.00 %
total sc in %	54.97 % 0.16 %		55.13 % 0.00 %		0.00 %

Shares class	For	Against Poll in				Abstain Poll not registered Represented shares with voting rights
Total	24,376,919		69,106 24,446,025	0	0	24,446,025
Agenda item 10 Election of members to the Election Committee
Ordinær	24,446,025	O	24,446,025	0	0	24,446,025
votes cast in %	100.00 %	0.00 %		0.00 %
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %
total sc in %	55.13 %	0.00 %	55.13 %	0.00 %	0.00 %
Total	24,446,025	0	24,446,025	0	0	24,446,025
Agenda item 11 Election of Auditor
Ordinær	24,446,025	0	24,446,025	0	0	24,446,025
votes cast in %	100.00 %	0.00 %		0.00 %
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %
total sc in %	55.13 %	0.00 %	55.13 %	0.00 %	0.00 %
Total	24,446,025	9	24,446,025	0	0	24,446,025
Agenda item 12 Authorisation to issue shares
Ordinær	24,446,025	0	24,446,025	0	0	24,446,025
votes cast in %	100.00 %	0.00 %		0.00 %
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %
total sc in %	55.13 %	0.00 %	55.13 %	0.00 %	0.00 %
Total	24,446,025	0	24,446,025	O	0	24,446,025
Agenda item 13 Authorisation to acquire treasury shares
Ordinær	24,446,025	0	24,446,025	0	0	24,446,025
votes cast in %	100.00 %	0.00 %		0.00 %
representation of sc In %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %
total sc in %	55 13 %	0.00 %	55.13 %	0.00 %	0.00 %
Total	24,446,025	0	24,446,025	0	0	24,446,025

Registrar for the company:

Signature company:

NORDEA BANK ABP, FILIAL NORGE

VISTIN PHARMA ASA

Share information

	Name Total number of shares Nominal value Share capital Voting rights
Ordinær	44,344,592	1.00 44,344,592.00 Yes
Sum:

§ 5-17 Generally majority requirement

requires majority of the given votes

§ 5-18 Amendment to resolution

Requires two-thirds majority of the given votes
like the issued share capital represented/attended on the general meeting